(NYSE: BHVN) Biohaven's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.82%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.29%.
Biohaven's earnings in 2026 is -$647,677,000.On average, 20 Wall Street analysts forecast BHVN's earnings for 2026 to be -$451,080,726, with the lowest BHVN earnings forecast at -$486,914,242, and the highest BHVN earnings forecast at -$385,737,256. On average, 20 Wall Street analysts forecast BHVN's earnings for 2027 to be -$356,724,154, with the lowest BHVN earnings forecast at -$473,634,762, and the highest BHVN earnings forecast at -$252,475,724.
In 2028, BHVN is forecast to generate -$293,066,967 in earnings, with the lowest earnings forecast at -$467,732,772 and the highest earnings forecast at -$67,978,287.